Finder's Pick for
Beginners
AbbVie is a drug manufacturers-general business based in the US. AbbVie stocks (ABBV.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $152.5 – an increase of 10.17% over the previous week. AbbVie employs 50,000 staff and has a trailing 12-month revenue of around $56.7 billion.
How to buy stocks in AbbVie
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ABBV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Finder's Pick for
Global Trading
Finder's Pick for
Commodity Stocks
Finder's Pick for
Free Trades
What's in this guide?
- Can I buy shares in AbbVie?
- Has coronavirus impacted AbbVie shares?
- AbbVie shares summary
- Compare share dealing platforms
- Is AbbVie stock a buy or sell?
- AbbVie performance over time
- Is AbbVie suitable for ethical investing?
- Are AbbVie shares over-valued?
- AbbVie's financials
- How volatile are AbbVie shares?
- Does AbbVie pay a dividend?
- Other common questions
AbbVie stock price (NYSE:ABBV)
Use our graph to track the performance of ABBV stocks over time.AbbVie shares at a glance
Information last updated 2022-06-24.
| Latest market close | $152.34 |
|---|---|
| 52-week range | $102.35 - $174.43 |
| 50-day moving average | $150.67 |
| 200-day moving average | $135.51 |
| Wall St. target price | $163.01 |
| PE ratio | 21.4388 |
| Dividend yield | $5.42 (4.08%) |
| Earnings per share (TTM) | $6.97 |
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
1 - 6 of 6
Online stock trading
Is it a good time to buy AbbVie stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
AbbVie price performance over time
Historical closes compared with the close of $152.34 from 2022-06-24
| 1 week (2022-06-17) | 10.17% |
|---|---|
| 1 month (2022-05-23) | 2.91% |
| 3 months (2022-03-21) | N/A |
| 6 months (2021-12-21) | N/A |
| 1 year (2021-06-25) | 34.84% |
|---|---|
| 2 years (2020-06-25) | 57.07% |
| 3 years (2019-06-25) | 131.87% |
| 5 years (2017-06-23) | 109.72% |
Is AbbVie under- or over-valued?
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's P/E ratio
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, AbbVie shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AbbVie's PEG ratio
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.4 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
AbbVie financials
| Revenue TTM | $56.7 billion |
|---|---|
| Operating margin TTM | 35.41% |
| Gross profit TTM | $38.9 billion |
| Return on assets TTM | 8.55% |
| Return on equity TTM | 83.12% |
| Profit margin | 22% |
| Book value | $9.22 |
| Market capitalisation | $264.1 billion |
TTM: trailing 12 months
AbbVie's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
AbbVie's total ESG risk score
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 01/01/2019) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
AbbVie's environmental score
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
AbbVie share dividends
Dividend payout ratio: 41.98% of net profits
Recently AbbVie has paid out, on average, around 41.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 4.08% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $5.42 per share.
While AbbVie's payout ratio might seem fairly standard, it's worth remembering that AbbVie may be investing much of the rest of its net profits in future growth.
AbbVie's most recent dividend payout was on 16 May 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 April 2022 (the "ex-dividend date").
AbbVie share price volatility
Over the last 12 months, AbbVie's shares have ranged in value from as little as $102.3545 up to $174.4275. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.8113. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
Find the best investment newsletters in Canada
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…
Sectors and stocks that might protect you from rising interest rates
Here are some investment ideas that could do well despite rising interest rates.
Read more…
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…More guides on Finder
-
How to buy Acadian Timber stock in Canada
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
-
How to buy Mobilicom Limited (MOB) stock in Canada when it goes public
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
-
How to buy Consumer Staples Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
-
How to buy Schwab U.S. REIT ETF stock in Canada
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
-
How to buy iShares US Consumer Staples ETF stock in Canada
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
-
How to buy Vanguard Real Estate Index Fund ETF Shares stock in Canada
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
-
How to buy SPDR S&P Insurance ETF stock in Canada
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
-
How to buy Financial Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
-
How to buy Invesco Dynamic Energy Exploration-and-Production ETF stock in Canada
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
-
How to buy First Trust Natural Gas ETF stock in Canada
Steps to owning and managing FCG stock, with 24-hour and historical pricing before you buy.